Classic and Atypical Late Ingantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and Genetic Aspects, and Treatment Outcome with Cerliponase Alfa
Norberto Guelbert,Oscar Mauricio Espitia Segura,Carolina Amoretti,Angélica Arteaga Arteaga,Nora Graciela Atanacio,Sabrina Bazan Natacha,Ellaine Doris Fernandes Carvalho,Maria Denise Fernandes Carvalho de Andrade,Inés María Denzler,Consuelo Durand,Erlane Ribeiro,Juan Carlos Giugni,Gabriel González,Dolores González Moron,Guillermo Guelbert,Zulma Janneth Hernández Rodriguez,Katiane Embiruçu Emilia,Marcelo Andrés Kauffman,Nury Isabel Mancilla,Laureano Marcon,Alessandra Marques Pereira,Carolina Fischinger Moura de Souza,Victor Adrián Muñoz,Ricardo Andrés Naranjo Flórez,André Luiz Pessoa,María Victoria Ruiz,Martha Luz Solano Villareal,Norma Spécola,Lina Marcela Tavera,Javiera Tello,Mónica Troncoso Schifferli,Sonia Ugrina,María Magdalena Vaccarezza,Diane Vergara,María Mercedes Villanueva
DOI: https://doi.org/10.1016/j.ymgmr.2024.101060
IF: 2.082
2024-02-03
Molecular Genetics and Metabolism Reports
Abstract:Introduction Late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), is a neurodegenerative autosomal recessive disease caused by TPP1 gene variants , with a spectrum of classic and atypical phenotypes. The aim of treatment is to slow functional decline as early as possible in an attempt to improve quality of life and survival. This study describes the clinical characteristics as well as the response to treatment with cerliponase alfa. Materials and methods A retrospective study was conducted in five Latin-American countries, using clinical records from patients with CLN2. Clinical follow-up and treatment variables are described. A descriptive and bivariate statistical analysis was performed. Results A total of 36 patients were observed (range of follow-up of 61–110 weeks post-treatment). At presentation, patients with the classic phenotype ( n = 16) exhibited regression in language (90%), while seizures were the predominant symptom (87%) in patients with the atypical phenotype ( n = 20). Median age of symptom onset and time to first specialized consultation was 3 (classical) and 7 (atypical) years, while the median time interval between onset of symptoms and treatment initiation was 4 years (classical) and 7.5 (atypical). The most frequent variant was c.827 A > T in 17/72 alleles, followed by c.622C > T in 6/72 alleles. All patients were treated with cerliponase alfa, and either remained functionally stable or had a loss of 1 point on the CLN2 scale, or up to 2 points on the Wells Cornel and Hamburg scales, when compared to pretreatment values. Discussion and conclusion This study reports the largest number of patients with CLN2 currently on treatment with cerliponase alfa in the world. Data show a higher frequency of patients with atypical phenotypes and a high allelic proportion of intron variants in our region. There was evidence of long intervals until first specialized consultation, diagnosis, and enzyme replacement therapy. Follow-up after the initiation of cerliponase alfa showed slower progression or stabilization of the disease, associated with adequate clinical outcomes and stable functional scores. These improvements were consistent in both clinical phenotypes.
genetics & heredity